metabolic dysfunction–associated steatotic liver disease

Overview

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is currently the most prevalent chronic liver disease worldwide, affecting approximately one-third of the global population. The condition is defined by hepatic fat accumulation (steatosis) occurring in the context of metabolic dysfunction—encompassing obesity, insulin resistance, type 2 diabetes, arterial hypertension, and dyslipidemia—in the absence of significant alcohol consumption or other competing causes of liver injury. MASLD represents a histological spectrum ranging from simple steatosis to the more aggressive inflammatory subtype, metabolic dysfunction–associated steatohepatitis (MASH), which can drive progressive hepatic fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality. The disease is the hepatic manifestation of systemic metabolic derangement, closely linked to cardiovascular disease, type 2 diabetes, and cardiovascular-kidney-metabolic (CKM) syndrome, and is now the second leading indication for liver transplantation in the United States.

The pathogenesis of MASLD is multifactorial, involving dysregulated lipid metabolism, oxidative stress, chronic low-grade inflammation, gut microbiome perturbation, and immune-mediated hepatocellular injury. Key molecular mediators include proinflammatory cytokines (such as interleukin-1 beta), nuclear factor kappa B (NF-κB) signaling, TLR4 pathway activation, transforming growth factor-beta–driven fibrogenesis, and disruption of fatty acid oxidation via pathways involving PPARA (peroxisome proliferator-activated receptor alpha) and PRKAA1 (AMP-activated protein kinase). Lipid droplet dynamics, ferroptosis, and dysregulation of the PI3K/AKT/mTOR pathway further contribute to disease progression. The condition exhibits marked racial and sex-specific heterogeneity in incidence, progression, and clinical outcomes, reflecting the interplay of genetic polymorphisms, epigenetic factors, and environmental exposures.

Focus of Latest Publications

Recent publications on metabolic dysfunction–associated steatotic liver disease (MASLD) have focused heavily on noninvasive detection, risk stratification, and real-world disease burden. One study examined the progression of metabolic dysfunction-associated steatohepatitis (MASH) to cirrhosis, decompensation, and mortality, with particular attention to the utility of non-invasive testing (NIT) for identifying MASH and estimating incidence rates and time to progression. In a population-based Greek adult cohort, MASLD prevalence was assessed using validated NITs, including the Liver Fat Score and the index of nonalcoholic steatohepatitis, and higher Mediterranean diet adherence was associated with lower odds of MASLD without steatohepatitis. Another survey study in people with type 2 diabetes highlighted marked racial and ethnic differences among those at risk of MASLD and related complications, underscoring the importance of social determinants of health in this population.

Several publications investigated clinical and biochemical markers linked to MASLD severity. In women with obesity-associated MASLD, the platelet-activating factor pathway was studied by evaluating hepatic expression of the platelet-activating factor receptor and circulating lipoprotein-associated phospholipase A2 across disease stages. Another study focused on fibroblast activation protein (Fap), a serine protease upregulated in chronic liver disease, to assess its involvement in MASLD and its downstream effects on circulating substrates such as fibroblast growth factor 21 and α2-antiplasmin. In children and adolescents with obesity, a parsimonious prediction model incorporating age, sex, BMI SDS, and waist circumference SDS showed robust performance for early identification of MASLD and outperformed HOMA-IR and adult-derived indices, while metabolic markers such as insulin, AST, ALT, and HOMA-IR increased with steatosis severity.

Intervention and mechanistic studies also featured prominently. Lactoferrin was tested in obese children and adolescents with MASLD in a randomized controlled study. Herbal and natural product investigations included Pueraria montana var. lobata root extract, which reduced lipid accumulation, inflammation, liver injury, and fibrosis in mice and was linked to increased mitochondrial β-oxidation and mitochondrial-peroxisome contact through direct activation of CPT1A signaling. The active components of the Danshen-Shanzha herb-pair were reported to protect against MASLD by synergistically promoting fatty acid oxidation via activation of PPARα, Plin-5, and Plin-2. Swertia mussotii was also studied in NAFLD models, where it reduced body weight, serum lipids, hepatic lipid accumulation, inflammation, and oxidative stress, while restoring dysregulated metabolic pathways and activating the SIRT1/AMPK axis, with downstream effects on ACC, SREBP-1c, FASN, and PPAR-γ.

Lifestyle and epidemiologic studies further reinforced the metabolic context of MASLD. In older adults in longevity regions of China, higher physical activity was inversely associated with NAFLD prevalence, although household-only or leisure-only activity was not significantly associated. A clinical dialogue podcast emphasized that obesity is strongly linked to MASLD and that the condition is often underdiagnosed because it is frequently asymptomatic. Across these publications, MASLD was consistently framed as a metabolically driven liver disease in which obesity, insulin resistance, oxidative stress, and related cardiometabolic factors shape risk, detection, and progression.

Key Publications

• NEWJun Progression of MASH to cirrhosis, decompensation, and mortality, and the utility of NITs for detection and risk stratification. (Hepatology communications, 2026, PMID 42319114): "This study assessed the use of non-invasive testing (NIT) in MASH identification and estimated incidence rates and time-to-disease progression."
• NEWJun High performance deep-learning model for the diagnosis of auto-immune hepatitis based on histological whole slide images. (Virchows Archiv : an international journal of pathology, 2026, PMID 42301307): "it achieved an AUC of 0,98 vs. MASH,"
• NEWJun Characterizing Social Determinants of Health in Patients With Type 2 Diabetes and Liver Disease: Cross-Sectional Survey Study. (JMIR formative research, 2026, PMID 42296541): "There are marked racial and ethnic differences among people with T2DM at risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and related complications."
• Jun Obesity, Liver Disease, and the Patient Voice: A Clinical Dialogue Podcast. (Advances in therapy, 2026, PMID 42250074): "...metabolic dysfunction-associated steatotic liver disease (MASLD), a condition in which the liver stores too much fat because the body's metabolism is not working properly."
• Jun Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease. (Scandinavian journal of gastroenterology, 2026, PMID 42233208): "The aim of this study was to investigate the involvement of FAP in metabolic dysfunction-associated steatotic liver disease (MASLD)."
• Jun Clinical utility of a novel index for predicting metabolic dysfunction-associated steatotic liver disease risk in children. (European journal of pediatrics, 2026, PMID 42223658): "We aimed to develop a simple, clinically applicable model for the early identification of metabolic dysfunction-associated steatotic liver disease (MASLD) in pediatric obesity."
• Jun Untargeted Metabolomic Analysis Reveals the Mechanism Underlying Swertia mussotii Treatment on Rats With Non-Alcoholic Fatty Liver Disease Using UPLC-Q-TOF/MS. (Biomedical chromatography : BMC, 2026, PMID 42108548): "Swertia mussotii (SM) is a traditional Tibetan medicine and can effectively treat hepatopathies like non-alcoholic fatty liver disease (NAFLD)."
• May Higher Mediterranean diet adherence is associated with lower odds of metabolic dysfunction-associated steatotic liver disease in Greek adults: A noninvasive population-based assessment. (Nutrition research (New York, N.Y.), 2026, PMID 41967401): "We hypothesized that higher adherence to the Mediterranean diet, is inversely associated with the presence of MASLD."
• Apr Pueraria montana var. lobata Root Extract Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease by Increasing Mitochondrial β-Oxidation and Mitochondrial-Peroxisome Contact. (Phytotherapy research : PTR, 2026, PMID 41947488): "We aim to evaluate the effects of Pueraria montana var. lobata extract (PLE) on the development of inflammation and the progression to metabolic dysfunction-associated steatotic liver disease (MASLD) by investigating the effects and underlying mechanisms both in vivo and in vitro under metabolic stress."
• May Platelet-Activating Factor Pathway in Women With Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity. (Obesity (Silver Spring, Md.), 2026, PMID 41885053): "This study aimed to investigate the platelet-activating factor (PAF) pathway in obesity-associated metabolic dysfunction-associated steatotic liver disease (MASLD) by evaluating hepatic expression of the PAF receptor (PAFR) and circulating levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) across different stages of disease severity."